

Inherited Thrombophilia*: Part 1

David A. Lane¹, Pier M. Mannucci², Kenneth A. Bauer³, Rogier M. Bertina⁴, Nikolay P. Bochkov⁵, Victor Boulyjenkov⁶, Mammen Chandy⁷, Bjorn Dahlbäck⁸, E. K. Ginter⁹, Joseph P. Miletich¹⁰, Frits R. Rosendaal⁴, Uri Seligsohn¹¹

From the ¹Charing Cross and Westminster Medical School, London, UK; ²IRCCS Maggiore Hospital, Milan, Italy; ³Beth Israel Hospital, Boston, USA; ⁴University Hospital Leiden, The Netherlands; ⁵Research Centre of Medical Genetics, Moscow, The Russian Federation; ⁶WHO, Switzerland; ⁷Christian Medical College Hospital, Vellore, India; ⁸University of Lund, Malmö, Sweden; ⁹Institute of Clinical Genetics, Moscow, The Russian Federation; ¹⁰Washington University, St Louis, USA; ¹¹Institute of Thrombosis and Hemostasis, Tel Hashomer, Israel

Introduction

Although familial clustering of venous thromboembolic events was observed at the start of this century, it was not until the late nineteenth century before our insight into the organization of the haemostatic and fibrinolytic systems was sufficiently complete to enable a start to be made on a systematic search for genetic defects associated with familial thrombosis. The discovery that heterozygosity of antithrombin deficiency co-segregated with the thrombotic tendency in affected families seemed to make a strong case for the association between single gene defects and thrombosis. The results of these systematic studies had been in part very fruitful and could be considered in the context of two principle endogenous anticoagulant pathways (Fig. 1), the antithrombin-heparan sulphate pathway and the protein C/protein S (PC/PS) pathway. However, only three single gene disorders had been identified that were associated with a significant increase in the risk for venous thromboembolism in families identified through a symptomatic deficient patient, with one of antithrombin, PC or PS deficiency.

The awareness that in 85% of families predisposed to thrombosis no explanation could be found for the clustering of this disorder stimulated the search for alternative approaches. A major breakthrough in the study of familial thrombosis has been achieved during the past two years. Firstly, the concept and investigation of activated protein C resistance (APC-R) was introduced and, secondly, a mutation in the factor V gene (1691 G → A in exon 10, leading to 506A1g to Gln) was identified as the molecular basis for the phenotype of APC-R in the large majority of affected individuals (2, 3). This mutation, which is associated with a significant increase in thrombotic risk (3–5), has been found in about 50% of selected families with thrombophilia and in 20% of consecutive patients with thrombosis. A consequence of this advance has been a conceptual change in how thrombophilia is viewed, which has implications for diagnosis and treatment of the disorder. This review [published in two parts, see also (6)] attempts to summarise recent progress and to present recommendations for diagnosis, treatment and research in developed and developing countries.

Correspondence to: Dr D. A. Lane, Department of Haematology, Charing Cross and Westminster Medical School, Hammer Smith, London W6 8RF, UK – FAX: +181 846 7111, e-mail: d.lane@cxwms.ac.uk

* Based upon the World Health Organisation report of a Joint World Health Organisation/International Society on Thrombosis and Haemostasis Meeting held in Geneva, 6–8 November 1995. Published with permission of the World Health Organisation. Meeting Rapporteur: ISTH Secretariat, WHO Secretariat.

Pathogenesis of Thrombophilia and Definition of Inherited Thrombophilia

Thrombophilia is a *tendency* to thrombosis. The predisposing defects do not necessarily cause continuous clinical impairment; they need only weaken the ability to cope with fluctuations induced by interactions with the environment. Clinicians usually apply the term thrombophilia only to a subset of patients with atypical thrombosis. Frequently cited features include: (1) early age of onset; (2) frequent recurrence; (3) strong family history; (4) unusual, migratory or widespread locations; and (5) severity out of proportion to any recognized stimulus. There are patients (see below) with fulminant thrombophilia who, without therapy, thrombose continuously. But in most patients thrombosis is episodic, separated by often prolonged asymptomatic periods. The discontinuity suggests that there is some trigger for each event, perhaps a direct stimulus, a temporary deterioration of intrinsic resistance, or some combination of these factors.

The term inherited thrombophilia acknowledges the presence of an inherited factor that by itself predisposes towards thrombosis but due to the episodic nature of thrombosis, requires interaction with other components (inherited or acquired) before onset of the clinical disorder, see Fig. 2. Undoubtedly the concept of inherited thrombophilia is an operational one, the definition of which has undergone continuous refinement. It was originally based upon early presentation of thrombosis, usually coupled with inherited phenotypic abnormality of one of the inhibitory proteins, antithrombin, PC or PS. Progress in the molecular basis of thrombosis has enabled a more genetically based definition to be formulated: *Inherited thrombophilia is a genetically determined tendency to venous thromboembolism. Dominant abnormalities or combinations of less severe defects may be clinically apparent from early age of onset, frequent recurrence or family history. Milder traits may be discovered only by laboratory investigation. All genetic influences and their interaction are not yet understood.*

The identified and potential genetic factors predisposing for thrombophilia discussed fully below are summarised in Table 1. In its footnote are listed some of the many potential interacting acquired risk factors.

Molecular Genetic Basis of Inherited Thrombophilia

In what follows there will be a summary of the available information on the nature and heterogeneity of the molecular defects associated with the established genetic risk factors for venous thrombosis: antithrombin deficiency, PC deficiency, PS deficiency and factor V gene mutation. In the subsequent paragraphs those genetic defects will be





Fig 1 Representation of the two principle anticoagulant pathways known to be important in the regulation of coagulation proteinase activity. To the left of each diagram is a simplified view of the coagulation cascade illustrating the positive 'procoagulant' feedback loops by which thrombin activates factors V and VIII. To the right are the 'anticoagulant' pathways by which excessive activation of coagulation is prevented. These pathways involve antithrombin (which directly inhibits the coagulation proteinases such as factor Xa and thrombin), and PC/PS (which inactivate factor Va and factor VIIIa). PS normally forms a complex with C4bBP and it is only the free form of PS that acts as a cofactor for PC.

reviewed for which the available studies still do not permit definitive statements to be made on their association with a thrombotic risk.

Antithrombin Deficiency

Antithrombin is a single chain plasma glycoprotein (58 kDa) which belongs to the superfamily of the Serine Protease Inhibitors (serpins). It is synthesized in the liver and its concentration in plasma is 2.5 μ M. Antithrombin is the primary inhibitor of thrombin and also inhibits most of the other activated serine proteinases involved in blood coagulation (factor Xa, factor IXa, factor XIa, factor XIIa, kallikrein). It is therefore one of the most important physiological regulators of fibrin formation.

Inactivation of proteinases by antithrombin occurs via the formation of an irreversible 1:1 molar complex, in which Arg393 forms a stabilised bond with the active site of the proteinase. The stable bond forms as the proteinase attempts to cleave the inhibitor. Arg 393-Ser 394 bond (this bond is at the reactive centre of antithrombin and is




Fig 2 Venous thrombosis can be caused by interacting genetic and acquired risk factors.

commonly referred to as the P1-P1' bond). Inhibition of most of the blood coagulation proteinases is relatively slow, but can be accelerated at least 1000-fold by the binding of heparin (and heparin-like compounds, such as endothelial cell heparan sulphate) to antithrombin. The interaction between heparin and heparin-binding domains in antithrombin results in a conformational change of the molecule which facilitates its interaction with the proteinase. Inactive antithrombin-serine proteinase complexes are rapidly cleared from the circulation. More information on the structure, biochemistry and mechanism of action of antithrombin can be found in a number of recent reviews (7-9).

Human antithrombin cDNA clones have been isolated and sequenced (10, 12). The gene coding for antithrombin is localized on chromosome 1 between 1q23 and 1q25 (13), it is 13 480 bp long and contains seven exons (1, 2, 3A, 3B, 4, 5, 6) (14), its nucleotide sequence has been recently completed (15). Several sequence variations or polymorphisms have been described within the human gene [for reviews see (7-9)], including a highly polymorphic trinucleotide repeat sequence in intron 4. The latter, particularly, seems useful for haplotype analysis in the study of recurrent mutations or linkage analysis (16).

Antithrombin deficiency is a heterogeneous disorder. The subclassification of antithrombin deficiency was originally based mainly on the results of functional and immunologic assays in plasma. Later, after more information had become available on the actual mutations in the antithrombin gene, the nomenclature was modified (17, 18). Presently we recognize type I antithrombin deficiency (identified by a concordant

Table 1 Possible causes of inherited thrombophilia

<i>(I) Inherited</i>		
Antithrombin deficiency	PC deficiency	PS deficiency
APC R/factor V 506Arg	Dysfibrinogenaemia	Thrombomodulin to Gln
<i>(ii) Acquired/Inherited (precise relative contribution as yet uncertain)</i>		
Hyperhomocysteinemia	Elevated factor VIII	Elevated fibrinogen?
<i>(iii) Potentially Inherited (but firm evidence lacking)</i>		
Plasminogen deficiency	Heparin cofactor II deficiency	Elevated histidine rich glycoprotein
Plasminogen activator deficiency?	Elevated plasminogen activator inhibitor?	

As discussed in the text, there is yet no firm evidence that conditions listed under (iii) are linked to inherited thrombophilia. The development of thrombosis is thought often to be caused by interaction between genetic and acquired factors, the best recognised of the latter being advancing age, immobilisation, major surgery, orthopaedic surgery and neurosurgery, pregnancy, puerperium, use of oestrogen-containing hormones, malignancies and the antiphospholipid syndrome.

reduction of both functional and immunological antithrombin) and type II antithrombin deficiency [also identified by a variant antithrombin molecule, which has a defect in the Reactive Site (II RS), a defect affecting the Heparin Binding Site (II HBS) or multiple functional defects (Pleiotropic Effect) (II PE)] From a clinical point of view antithrombin deficiency is heterogenous, see below with mutations causing type II HBS deficiency being of much less risk than those causing the other subtypes (18, 19)

In 1991 the first database of antithrombin gene mutations was published (20) A revision of this database became available in 1993 as a report of the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (SSC ISTH) (18) In the 1993 database 39 distinct mutations and nine whole or partial gene deletions (>30 bp) are listed that have been found in type I antithrombin deficiency These mutations will introduce a frameshift (plus premature termination codon), a direct termination codon, a change in mRNA processing or unstable translation products In the type II deficiencies 11 different mutations have been reported in the type II RS group, 11 in the type II HBS group and 9 in the type II PE group Most of the mutations found in type II RS patients concern the reactive site of antithrombin (P12, P10, P2, P1 and P1') Type II HBS mutations are located mainly on the A, C and D α helices, sites that have been proposed to be involved in heparin binding (21) Mutations producing pleiotropic effects (type II PE) interestingly all are located in strand 1C close to the C-terminal end of the protein, this region has been shown to be essential both for the stability of the protein and for the transmission of conformational changes that endow the protein with its antithrombin activity (both in the presence and absence of heparin) (22) Since the publication of the first revision of the mutation database several reports on novel mutations in the antithrombin gene have been published (23-27)

Recurrent mutations are found in all types of antithrombin deficiency, but especially in the type II HBS From the 21 distinct repeat mutations 9 involved a CpG dinucleotide (hotspot for mutation) Only preliminary information is available (16) that addresses the issue of whether these recurrent mutations are the result of independent mutations or of a founder effect (identity by descent)

PC Deficiency

PC is a vitamin K dependent plasma glycoprotein which is the precursor of the serine proteinase Activated Protein C (APC) PC is synthesized in the liver as a single chain molecule (62 kDa) Single chain PC is converted into a two chain molecule by removal of a dipeptide (Arg157 - Thr158) probably in the Golgi In plasma most of the PC is in the two chain form (41 kDa heavy chain and 21 kDa light chain), the concentration of PC in plasma is 65 nM and is reduced during treatment with oral anticoagulants

PC is a multimodular protein the amino terminal light chain contains a γ -carboxyglutamic acid rich domain (Gla-domain) and two Epidermal Growth Factor like domains (EGF domains) These domains have been found to be involved in the formation of Ca^{2+} -induced conformational changes, binding to phospholipid surfaces, the activation of the molecule and its interaction with other proteins (such as its cofactor PS), while the carboxyterminal heavy chain contains the serine proteinase moiety of the molecule

During coagulation PC can be activated by thrombin via cleavage of the Arg169-Lcu170 bond This reaction (which is normally very slow) can be greatly accelerated by the binding of thrombin to thrombo-

modulin, a transmembrane protein receptor present on the membrane of endothelial cells The APC, thus formed, inactivates the cofactors, factor Va and VIIIa, by selective proteolytic cleavages To do this efficiently APC needs to form a complex with PS on a suitable membrane surface Apart from these anticoagulant properties, APC also has antifibrinolytic properties and anti-inflammatory effects More detailed information on structural, biochemical and functional aspects of PC can be found in recent review articles (28-30)

Human cDNA clones have been isolated and sequenced (31, 32) Also the structure of the gene (PROC) has been resolved (33, 34) it contains 9 exons and 8 introns on 11 kb of genomic DNA The gene transcript is 1795 bp It contains a 5' untranslated region of 74 bp a protein coding region (exons 2-9) and a 3' untranslated region of 294 bp The gene has been mapped to the chromosome 2q13-q14 region (35)

A number of DNA sequence polymorphisms are known to occur in the PC gene, both in the promoter region and in the coding region (36, 37) None of these variations leads to an amino acid dimorphism All these polymorphisms have been formatted for detection by PCR This is also true for the two restriction fragment length polymorphisms (RFLPs), reported by te Lintel-Hekkert et al that are located ~7 kb 5' to the PROC gene (38)

PC deficiency is a heterogenous disorder (37, 39) A phenotypic subclassification has been proposed that is based on the results of functional and immunologic PC assays In type I PC deficiency there is a concordant reduction in PC activity and PC antigen, while in type II PC deficiency there is evidence for the presence of an abnormal PC molecule (reduced PC activity normal PC antigen) A further classification of the type II PC deficiency can be made by comparing the results of different functional tests (clotting test versus chromogenic test)

In May 1995, the first update of the data base of PROC gene mutations was published on behalf of the Subcommittee on Plasma Coagulation Inhibitors of the SSC ISTH (37) The database contains 331 entries derived from 315 unrelated probands In total 160 different mutations were reported that had resulted in type I or type II PC deficiency Surprisingly ~60% (n = 132) of the mutations (n = 28) causing type I PC deficiency are missense mutations Probably these amino acid substitutions lead to changes in the interactions with other residues and thus interfere with protein folding, a condition associated with rapid intracellular degradation of the protein Missense mutations leading to type II PC deficiency predominantly are located in surface and solvent accessible areas of the protein that are relevant for the function of the protein (like propeptide cleavage, calcium binding, activation, interaction with thrombomodulin, active site, substrate binding) (40, 41) Further, there are mutations in the promoter and 5' untranslated region, splice site abnormalities, small deletions and insertions (eventually leading to a premature termination codon) and nonsense mutations that also are responsible for type I deficiency

About 30% of the unique events occur in CpG dinucleotides and are C \rightarrow T and G \rightarrow A transitions Interestingly, 18 transitions in 16 different CpG dinucleotides form about 40% of all the entries in the 1995 database At present there is insufficient information to distinguish recurrent events from events that are identical by descent

PROC gene mutations have been reported now for 18 true homozygotes (9 of these had severe clinical symptoms) and 17 compound heterozygotes (8 with severe clinical symptoms) PROC gene mutation analysis has not however solved an important clinical and epidemiological issue that of clinically recessive and dominant forms of PC deficiency (see below) The 1995 database already lists 14 different mutations that have been found in both these types of PC deficiency

Table 2 PROS gene sequence variations in patients with phenotypic PS deficiency

Exon	Codon, sequ mutat	Predicted mutation	Ref
1	-25, Ins T	-25, Leu → Leu frameshift, stop	(64)
2	-2, G → T	-2, Arg → Leu	(68)
2	-1, G → A	-1, Arg → His	(68)
2	22, C → A	22, Cys → stop	(68)
2	26, A → C	26, Glu → Ala	(68)
2	31, T → G	31, Phe → Cys	(68)
2	37, C → T	37, Thr → Met	(68)
3	43, del A	43, Lys → Asn frameshift, stop	(144)
4	49, G → A	49, Arg → His	(68)
5	82, del T	82, Pro → Pro, frameshift, stop	(145)
5	103, C → A	103, Thr → Asn	(68)
6	155, A → G	155, Lys → Glu	(69)
8	204, A → G	204, Asp → Gly	(68)
8	208, G → A	208, Glu → Lys	(68)
8	217, A → G	217, Asn → Ser	(146)
8	220, del G	220, Gly → Glu frameshift, stop	(146)
8	224, C → G	224, Cys → Trp	(68)
8	224, T → C	224, Cys → Arg	(68)
9	261, del T	261, Leu → Trp frameshift, stop	(65)
9	267, del G	267, Gly → Gly frameshift, stop	(65)
10	335, G → A	335, Asp → Asn	(68)
10	340, G → T	340, Gly → Val	(65)
12	448, G → T	448, Gly → stop	(146)
13	467, T → G	467 Val → Gly	(65)
14	547-548, del AC	frameshift, stop	(146)
14	565, ins T	565, Val → Val frameshift, stop	
14	570, T → C	570, Met → Thr	(146)
14	578, ins C	578 Pro → Leu frameshift, stop	(65)
15	636, A → T	636 stop → Tyr new stop at 649	(64)
intron d	G → A	exon 4+1	(146)
intron e	G → A	exon 5+5	(68)
intron j	G → A	exon 10+1	(146)
intron j	G → A	exon 10+5	(64)

PS Deficiency

PS is a vitamin K dependent plasma glycoprotein (70 kDa). It is synthesized in the liver, but also in endothelial cells, megakaryocytes and Leydig cells in the testis. The concentration of PS in plasma is 25 µg/ml and is reduced during treatment with oral anticoagulants.

PS is a multimodular protein, it contains a γ-carboxyglutamic rich domain, a thrombin sensitive region, four epidermal growth factor like domains and a carboxyterminal region which is highly homologous to the sex hormone binding globulin (SHBG). PS serves as a non-enzymatic cofactor of activated protein C (APC) in the inactivation of factors Va and VIIIa probably by facilitating the formation of enzyme-

substrate complexes on the surface of phospholipid/platelet membranes. This APC-cofactor activity is destroyed by one of three proteolytic cleavages in the so-called "thrombin-sensitive region" (Arg49 Arg60, Arg70). In plasma PS circulates both free (40%) and in a 1:1 stoichiometric complex with C4b-binding protein (60%). The latter comprises 7 identical α chains (70 kDa) and one single β chain (45 kDa) which are linked to each other in the carboxyterminal region by disulphide bonds. The β chain contains the PS binding site. Two regions in PS have been reported to be involved in binding of the C4b binding protein (Gly605 to Ile614 and Gly420 to His434). Only the free form of PS has APC cofactor activity. More recently it has been reported that PS itself also has anticoagulant activity under well-defined conditions it may inhibit (in an APC-independent way) the activity of both the tenase (IXa-VIIIa) and prothrombinase (Xa-Va) complexes, some reactions being independent of the presence of C4b-binding protein (42-44).

A novel functional aspect of PS has been revealed recently from studies reporting on its binding to the receptor tyrosine kinase known as Rse/Tyro 3 (45) and to a specific receptor on vascular smooth muscle cells. This might indicate that PS also is involved in the regulation of cell proliferation. More detailed information on structural, biochemical and functional aspects of PS can be found in a recent review article (47).

Human PS cDNAs have been isolated and sequenced (48-50). From the cDNA nucleotide sequence the amino acid sequence of human PS has been derived. Two highly homologous PS genes have been identified and sequenced (51-53). The PROS or PSα gene is the active gene, it consists of 15 exons which are spread over 80 kb of genomic DNA and has been mapped to the chromosome 3 p11.1-3 p11.2 region (54). The PSβ gene shows 96.5% homology with PROS in exon sequences and the positions of the introns are virtually identical to those in the PROS gene. However the PSβ gene is a pseudogene, it contains only exons 2-15 and contains a large variety of detrimental aberrations (a splice site mutation, a frame shift mutation and three stop codons). With the use of a rare RFLP the pseudogene has been located within 4 cM of the PROS gene (55). Several DNA sequence polymorphisms have been reported in the PROS gene (48, 49, 56). Some of these have been very useful for tracking PS deficiency through families, for prenatal diagnosis and for evaluating the possibility of allelic exclusion in the case of the study of reverse transcripts of platelet PROS mRNA (57, 58).

Discussions on the subclassification of PS deficiency have yet to be finalized. Currently, two of the three proposed subclassification systems are still in use, the system proposed by Comp in 1990 (59) and the proposal recommended by the SSC ISTH in Munich, July 1992. Consistent with the subclassifications used for other hereditary deficiencies, type I deficiencies/defects result in a reduction of total PS antigen (and of free PS antigen and PS activity). Type II, or in Comp's notation type IIb, defines the presence of a functionally abnormal PS molecule (total PS antigen normal, free PS antigen normal but PS activity reduced). Type III PS deficiency (or in Comp's notation type IIa) is defined by normal total PS antigen but reduced free PS antigen and activity. Although this phenotype seems to be rather prevalent, it is not yet clear whether it is caused by a hereditary defect and if so whether it is linked to the PS locus. Recently Zoller et al reported that both type I and type III phenotypes are reflections of the same genotype (60). Furthermore, Duchemin et al reported among type III PS deficiencies an unusual high frequency (22%) of a mutation previously described as a rare polymorphism (61). It concerns a T → C transition in codon 460 resulting in the replacement of Ser460 by Pro in the

consensus sequence for the N-linked glycosylation of Asn458 (PS Heerlen) (62). The frequency of the PS Heerlen allele in the general population is 0.5% and not different from that in thrombophilic patients (0.7%). At present it is not clear why this genotype is so frequent among type III PS deficiencies.

The genetic analysis of the PROS genes of symptomatic PS deficient probands has been hampered and delayed by the structural complexity of the PROS gene and the existence of the highly homologous pseudogene. A further complication is the unexpectedly low yield of successful genetic analyses. In three separate studies mutations were only found in 50-60% of the patients, although all coding and flanking regions had been amplified and sequenced (63-65).

Only two large deletions in the PROS gene have been reported as a cause of a type I PS deficiency (66, 67). Again, the majority of genetic lesions causing a type I deficiency are single nucleotide substitutions, insertions and deletions. So far 33 unique events have been reported (see Table 2), but this number will increase rapidly in the near future. At present these numbers are too low to make any further analysis. Four different mutations have been reported that cause a type II PS deficiency (68, 69), two in the propeptide, one in the first EGF domain and one in the second EGF domain. Table 2 gives a summary of all the PROS gene mutations reported to date in symptomatic PS deficient patients. In 1995, in Jerusalem, the Subcommittee on Plasma Coagulation Inhibitors of the SSC ISTH decided to publish the first database of PROS gene mutations in 1996/1997.

Factor V Arg506 to Gln

Factor V is a single chain plasma glycoprotein (300,000 kDa). It is synthesized in the liver and in megakaryocytes. Human plasma has a concentration of 20 nM of this procofactor, while its concentration in platelets is 4 $\mu\text{g}/10^9$ platelets. During blood coagulation factor V is converted into factor Va by (meizo)thrombin and/or factor Xa. Thrombin-activated factor V is formed after cleavages of the Arg709-Ser710, Arg1018-Thr1019 and Arg1545-Ser1546 bonds. It is composed of an amino terminal fragment (heavy chain 105 kDa) and a carboxy terminal fragment (light chain 74 kDa) non-covalently linked via a tightly bound Ca^{2+} ion. Factor Va serves as a nonenzymatic cofactor in prothrombinase (factor Xa, phospholipids, Ca^{2+}) by increasing the catalytic efficiency approximately 2000-fold. Factor Va light chain is reported to contain the phospholipid binding site, while the heavy chain site is mainly responsible for the cofactor activity.

Factor Va is inactivated by proteolytic degradation of its heavy chain by APC, this inactivation is more efficient in the presence of phospholipids and Ca^{2+} and is according to some an ordered and sequential event with a first cleavage at Arg506 and subsequent inactivating cleavages at Arg306 and Arg679 (70). Others demonstrated that two random cleavages (mainly at Arg506 and Arg306) are involved and that both contribute to the inactivation of factor Va (71).

More recently it was reported that factor V is not only a procofactor in the prothrombinase reaction but also a cofactor in the inactivation of factor VIIIa by APC (72). More information on the structure and function of human factor V can be found in a recent review (73).

Partial and overlapping human factor V cDNAs have been isolated from HepG2 and human (fetal) liver cDNA libraries (74-76). From the nucleotide sequence, the complete amino acid sequence of factor V was derived. It consists of 2196 amino acids and shows a characteristic domain structure ($A_1-A_2-B-A_3-C_1-C_2$) that is also found in factor VIII. The characterization of the human factor V gene was reported in 1992 by Cripe et al. (77). Twenty five exons and 24 introns span approxi-

mately 80 kb genomic DNA. The nucleotide sequence of all coding and flanking regions has been determined. The factor V gene has been mapped to chromosome 1 (1q21-25) and is closely linked to the anti-thrombin gene (78). A number of nucleotide sequence variations in human factor V cDNAs have been identified (74-76, 79) but with some exceptions (79, 80) the allele frequencies have not been reported. The microsatellite marker DIS61 has been mapped within 4 cM of the factor V gene locus and has been used successfully for tracking the factor V gene in a family with hereditary APC-R (3).

In 1994 the single point mutation in the factor V gene was identified as the genetic defect causing the phenotype of APC-R in the vast majority of affected individuals (3, 5, 81). It involves a G \rightarrow A transition of nucleotide 1691 in exon 10, which predicts the synthesis of a variant factor V molecule (factor V 506Arg to Gln or factor V Leiden).

The mechanism by which the mutation leads to the phenotype of APC-R is still subject of detailed biochemical studies. However it is clear that the replacement of Arg506 by Gln will prevent cleavage of factor V(a) at this site by APC and by that delay the inactivation of factor Va (82, 83) either by preventing the conformational change necessary for the inhibitory cleavage at Arg306 or by preventing the kinetically more favourable inhibitory cleavage at Arg506.

So far the factor V 506Arg to Gln mutation is the only genetic defect identified in APC-R families. It has a relatively high frequency in Caucasian populations (up to ~6%) but a much lower frequency in the Japanese and other Eastern populations (~0%) (84). Preliminary evidence for a founder effect in the spread of this disorder was obtained from the results of haplotype analysis of 53 Dutch carriers of the mutation (3).

Other Candidates?

There are a number of other genetic defects or isolated deficiencies that have been implicated in contributing to the risk of thrombosis in families with thrombophilia. In most cases these have been based on observations in case-families. Sometimes genetic defects have been identified but no data on genotype-phenotype relationships are available as yet (85). In the next paragraphs the various candidates will be briefly discussed.

Hereditary dysfibrinogenemia is detected by a prolonged plasma thrombin time. Clinical symptoms vary from none, mild bleeding to venous or arterial thrombosis. The phenotype may follow recessive or dominant inheritance. Recently the evidence for a causal relationship between an isolated dysfibrinogenemia and venous thrombosis has been critically reviewed and discussed by a working party of the SSC Subcommittee on Fibrinogen of the ISTH (86). In that investigation 5 families (from 5 different countries) were identified in which apart of the proband, two or more family members had both the defect and thrombosis. In all five cases the genetic defect had been identified (two mutations in the $\text{A}\alpha$ chain, two mutations in the $\text{B}\beta$ chain and one mutation in the γ chain of fibrinogen). In one family only homozygotes for the mutation (fibrinogen Naples) were clinically affected. The relationship between the defect in the fibrinogen molecule and the phenotype of thrombophilia is still poorly understood. Further studies are hampered by the low frequency of dysfibrinogenemia in cohorts of patients with thrombosis (0.8%) (86).

Thrombomodulin (TM) is another component of the PC anti-coagulant pathway (47). It is a transmembrane protein synthesized by endothelial cells which acts as a receptor for thrombin and as cofactor of thrombin in the activation of PC. By analogy with PC and PS deficiencies, one would expect that deficiencies or defects in thrombo-

modulin may be associated with an increased risk of thrombosis. Unfortunately plasma is not an abundant source of TM and therefore cannot be used for the laboratory diagnosis of TM defects. Analysis of the TM genes in cohorts of symptomatic probands with a family history of thrombophilia did not reveal any alteration in the coding and flanking regions of the gene (0/30) in one study (Reitsma PH & Bertina RM unpublished observations) while four different mutations (4/87) were identified by a second group (85-87). To date there is still very limited information of the co-segregation of these mutations with thrombophilia in the families of the probands.

Recently mild *hyperhomocysteinemia* was found in 19% of patients with juvenile venous thrombosis and family studies showed that in most cases this phenotype was inherited (88). Two large patient-control studies have shown that hyperhomocysteinemia is a risk factor for recurrent thrombosis (89) and for thrombosis in unselected patients, among whom elevated levels were present in 10% (90). Severe hyperhomocysteinemia has a population prevalence of ~1/300,000 and is most frequently caused by homozygous *cystathionine β synthase* deficiency. Homocysteine is a sulphhydryl amino acid derived from metabolic conversion of methionine. Its intracellular metabolism occurs through remethylation to methionine or transsulphuration to cysteine. Cystathionine β-synthase is involved in the transsulphuration pathway. A small number of cases of severe hyperhomocysteinemia are caused by homozygous deficiency of *methylenetetrahydrofolate reductase*. Gene defects in both of these metabolic enzymes are implicated in mild hyperhomocysteinemia (91, 92). A recently described mutation with the molability of methylenetetrahydrofolate reductase may in the homozygous state be a significant and frequent cause for mild hyperhomocysteinemia (93).

Plasminogen deficiency and dysplasminogenemia have been reported frequently to be associated with thrombophilia. However, family studies reveal that in most families with a type I plasminogen deficiency (parallel reduction of plasminogen activity and antigen) only the proband suffers from thrombotic disease (94). In a recent retrospective analysis of 20 families, heterozygotes of a type I plasminogen deficiency were found to experience significantly more thrombotic events (although rather late in life) than their normal family members (95). The frequency of plasminogen deficiency in the general population seems to be slightly lower (0.4%) to that in cohorts of patients with thrombosis (1.3%) (96, 97). *Dysplasminogenemia* or type II plasminogen deficiency (reduced plasminogen activity, normal antigen) associated with substitution of Ala601 by threonine is a common variant in the Japanese population and seems not to be associated with thrombosis (98). Studies of plasminogen deficiency at the DNA level are still very rare.

In a model in which it is expected that reduced plasminogen levels may cause thrombophilia it seems reasonable to propose that an inherited elevated *Histidine Rich Glycoprotein (HRG)* level in plasma is also a risk factor for thrombosis. HRG (a non enzymatic protein) forms a 1:1 complex with plasminogen in plasma (via binding to its lysine binding sites) and thus reduces the free plasminogen concentration to around 50% (99). Complex formation with HRG interferes with the binding of plasminogen to fibrin. Although several families with thrombophilia and high HRG levels have been reported (100-101) there is still no formal evidence for its association. Surprisingly, recently two families have been reported where a partial deficiency of HRG seems to be associated with thrombophilia (102-103).

Another potential risk factor of thrombosis, deficiency of the *Tissue Factor Pathway Inhibitor (TFPI)* has been investigated but no mutation in TFPI genes of 30 symptomatic probands of families with throm-

bophilia (Reitsma PH & Bertina unpublished observations) could be found. Other potential candidate risk factors for thrombosis are *heparin cofactor II deficiency* and *β₂ glycoprotein I deficiency*. Laboratory analysis of large groups of patients with thrombophilia and of controls revealed however, that the frequency of heterozygotes for these defects among patients and controls is very similar (0.6% and 6% respectively) (104-105). Nevertheless a few families have been reported in which an isolated heparin cofactor II deficiency seems to segregate with the thrombophilia (106-107). In two families with a type II heparin II cofactor deficiency the lesion in the gene was identified (replacement of Arg 189 by His) (108). This mutation is thought to effect the dermatan sulphate binding site and is analogous to certain defects in type II HBS antithrombin deficiency that effect the heparin binding.

A last genetic defect that has been discussed during the last years with respect to its possible association with thrombophilia is a partial *factor XII* deficiency. Original studies from Mannhalter et al suggested a high frequency of heterozygotes for factor XII deficiency in cohorts of thrombophilic patients (109). Subsequent studies have not supported these findings (110).

Finally there is a phenotype that recently has been identified as a risk factor for thrombosis in large patient-control studies: elevated *factor VIII* levels (111). The heritability of this phenotype and the eventual underlying molecular defects have not been reported so far.

Epidemiology of Inherited Thrombophilia

Prevalence of Hereditary Thrombophilia

Venous thrombosis has an overall annual incidence of <1 in 1000. It is rare in the young, and becomes more frequent with advancing age. The true prevalence of hereditary thrombophilia is not yet known. It seems clear that we do not know all genetic abnormalities causing a tendency to venous thrombosis, since even in patients from families selected on the basis of a high number of unexplained thromboses in only about half an underlying defect will be found (112). This indicates that the prevalence of hereditary thrombophilia in the general population will be higher, possibly up to two fold than estimates from large prevalence studies on the known genetic defects. A high prevalence of hereditary thrombophilia will make this an important factor in the overall incidence of thrombosis. This may also be assessed by taking the presence of a positive family history into account. Among unselected consecutive patients with deep vein thrombosis a family history was reported by one out of every four patients (113). Even though a positive family history may occur by chance as venous thrombosis is not a rare disorder, these figures indicate that genetic causes are prominent in the etiology of venous thrombosis.

The prevalence of deficiencies of PC and antithrombin has been investigated in a very large study of almost 10,000 blood donors (114-117), Table 3. Repeated testing of the levels of these proteins coupled with family studies and DNA analysis led to estimates of 1 in 500 for PC deficiency and 1 in 5000 for type I antithrombin deficiency. This is in the same range of the findings of a previous study among over 5000 blood donors where 1 in 250 were considered PC deficient (118). Although some caution is needed in interpreting data based on studies among blood donors who are a self selected sample from the general population these seem to be fair estimates. Accepting the approximate prevalence of PC deficiency to be 1/350 the prevalence of severe (homozygous or compound heterozygous) deficiency will be $1/700 \times 1/700 = 4.9 \times 10^{-7}$. Offspring from related parents will of course have much higher risk of severe deficiency. The prevalence of severe anti-

Table 3 Prevalence of the major thrombophilic clotting abnormalities

	PC deficiency	PS deficiency	Antithrombin deficiency	APC R
<i>Healthy individuals</i>				
Tait et al (n = 9669) (114/117)	0.2%+		0.02% ¹	
Milcetic et al (n = 5422) (118)	0.4%			
Svensson and Dahlbäck (n = 130) (119)				7%
Rosendaal et al (n = 474) (4)				3%+
Ridker et al (n = 704) (120)				6%+
<i>Consecutive patients with first DVT</i>				
Heijboer et al (n = 277) (113)	3%	2%	1%	
Koster et al (n = 474) (125)	3%+	1%	1%	
Rosendaal et al (n = 471) (4)				20%+
<i>Thrombophilic patients</i>				
Briet et al (n = 113) (147)	8%	13%	4%	
Scharner et al (n = 158) (148)	9%	6%	5%	
Ben Tal et al (n = 107) (149)	6%	3%	7%	
Taberno et al (n = 204) (150)	1%	1%	0.5%	
Griffin et al (n = 25) (112)				52%

+ DNA confirmed ¹type I Antithrombin deficiency

thrombin deficiency is likely to be 100/1000 less than severe PC deficiency. There are no studies of sufficient size on PS deficiency among healthy individuals on which a reliable estimate of its prevalence can be based.

For APC-R, the groups that have been studied are not as large as in the blood donor studies. However, since the prevalence of this abnormality is an order of magnitude higher than the other inhibitor deficiencies, the estimates are as reliable. The estimates for Caucasians range from 3 to 7 percent (4/119/120), and for several studies are based on genetic investigation (4, 120). Since these estimates are also based on self-selected individuals without a history of cardiovascular disease or venous thrombosis, they are under rather than over-estimates. The prevalence at birth of homozygous factor V 506Gln mutation has been estimated at ~1/5000 (4).

Among consecutive patients with objectively confirmed deep vein thrombosis, deficiencies of PC, PS and antithrombin combined account for ~5%. APC-R is present in 20 percent of consecutive patients with deep-vein thrombosis (4, 121).

Several studies have focused on selected patients with venous thrombosis and usually found a higher prevalence of deficiencies of PC, PS and antithrombin than has been reported among unselected consecutive patients. Different criteria were used in selecting the patients for these series: some authors included patients who experienced a first thrombosis at a young age, others studied individuals with recurrent thrombotic events, or thrombotic events that occurred in the absence of any of the classical risk factors for venous thrombosis, while some included individuals with a positive family history. Because of these heterogeneous inclusion criteria, the prevalences that have been reported in these studies should not be compared too closely. The prevalences that have been reported among selected patient groups for deficiencies of PC, PS and antithrombin are mostly between 5 and 10%, much higher than the prevalences found in the population studies, and also somewhat higher than the frequency among consecutive unselected patients. These higher prevalences in patients with thrombosis than in healthy individuals, and in thrombophilic individuals as compared to unselected patients, also indicate that these deficiencies indeed lead to venous thrombosis and venous thrombophilia. APC-R appears to account for half of all cases of hereditary thrombophilia, and clearly

emerges from Table 3 as the most important cause of hereditary thrombosis, and perhaps of venous thrombosis in general.

Risk of Venous Thrombosis

The risk of venous thrombosis for individuals with clotting factor gene abnormalities has largely been investigated by two approaches: first by studies in family members of probands with one of these abnormalities, and second by population-based studies (case control studies). These different approaches do not necessarily yield the same information. The former are based on families in which the heritability of the abnormality has been shown, by including only families with one or more individuals with the clotting abnormality, apart from the proband who is both symptomatic for thrombosis and has the clotting defect. In the analysis, typically the occurrence of thrombosis is compared between the family members with and without the clotting factor abnormality, while the proband is excluded from the analysis. Since heritability is a prerequisite in studies of this design, they are most fitting to directly answer questions concerning risks of genetic disorders. In population-based studies, patients with thrombosis are compared to healthy individuals with regard to the prevalence of clotting factor abnormalities. These case control studies yield relative risk estimates, which indicate how much higher the risk of thrombosis is for an individual with a particular risk factor compared to an individual without that factor. Since only individuals are included and not families, no direct statements about heritability result from these studies. Furthermore, case control studies can only yield estimates of relative risks, not of absolute (life time) risks.

When consecutive patients are included in a population-based study (with population-controls), the results associating a particular risk factor with thrombosis apply indiscriminately to all individuals with that abnormality in the population. The results from family studies are based on families that stood out and were recognised because of a conspicuous high frequency of thrombosis; strictly speaking, these results only apply to families detected in a similar way. In other words, population-based studies yield an average risk for individuals with a particular abnormality, whereas family studies are conducted among those with higher risks. Since it is likely, and has now been shown to be

true for APC-R that many families with thrombophilia display more than one genetic abnormality one should exercise extreme caution in applying results from family studies to unselected individuals or results from population-based studies to thrombophilic families. If an individual is identified as carrying a thrombogenic abnormality by means of a study among the general population in all likelihood he only carries that one abnormality. If he is found as proband of a family with thrombophilia he might well carry two or more and if he is an unselected patient with thrombosis he may well be one of both.

Antithrombin Deficiency

When the data from all the available family reports of antithrombin deficiency are combined it appears to confer a higher risk of thrombosis than deficiencies of PC and PS. Thrombosis is not uncommon before age 16 and about half of the patients from these reported families experienced a first thrombotic event before age 25 (122, 123). Antithrombin deficiency especially has a much higher risk of thrombosis in pregnancy than deficiencies of PC or PS (124). The fifty fold difference in the prevalence among patients with a first event of deep venous thrombosis and the prevalence in a healthy population (113, 114, 125) also suggests a higher thrombotic risk in antithrombin deficiency than in PC deficiency, although such a difference could not be substantiated in a population-based study (125). There is some debate whether the more severe form of thrombophilia caused by antithrombin deficiency might also result in increased mortality (126, 127) in some pedigrees fatal thromboses have been observed (128) but in historic studies of Dutch pedigrees no excess mortality was evident (24, 129).

PC Deficiency

Since 1981 (130) many families with hereditary protein C deficiency have been reported. The risk of thrombosis appears not to be different for the different types of protein C deficiency (type I low plasma level and type II low activity) nor for the large number of mutations identified in PC deficiency (37). In family studies it has been shown that family members who are PC deficient have an increased risk of venous thrombosis (about 8-10 fold) and that by age 40 about half of them will have experienced at least one thrombotic event (131, 132). In a population-based study (125), a relative risk estimate of 7 has been reported which (surprisingly in view of the comments made above) is very similar to the relative risk derived from family studies. The prevalences reported in unselected patients with first thrombotic event (3%) (113, 125) and healthy individuals from the general population (0.2%) (117) also support a relative risk of this size or slightly higher.

These data all apply for heterozygous PC deficiency in which PC activity on average is 50 percent of normal. The rare homozygous patients with no PC activity in plasma has a much higher risk of thrombosis and develop purpura fulminans shortly after birth (see below).

PS Deficiency

Since 1984 (133, 134) many families have been reported with venous thrombophilia and PS deficiency. It is not clear whether the three different subtypes that have been described (types I, II and III) confer similar risks of thrombosis. It is very difficult to arrive at risk estimates for PS deficiency since the prevalence in the general population is unknown there are no reports from family studies formally

assessing the relative risk the molecular basis in many cases remains unclear and several families with APC-R appear to have been misclassified as PS deficient (type II) (135). In one population based case control study the prevalence of individuals with repeatedly low levels of PS did not differ between cases and controls which does not support an association of PS deficiency and venous thrombosis (125). It is difficult to reconcile this finding with the reports from several families as well as the higher prevalence of PS deficiency in selected patients with thrombophilia than in unselected patients with a first event (Table 2). Although the available evidence generally leads to the conclusion that PS deficiency increases the risk of thrombosis this evidence is much less solid than for PC deficiency. Homozygous PS deficiency has been reported and while extremely rare appears to be as severe as homozygous PC deficiency (see below).

APC R/Factor V 506Arg to Gln

In a study in 34 families with APC-R the life time risk of thrombosis was clearly higher in family members with this phenotype than in those who did not (119). At age 50, about 25 percent of individuals with APC-R had experienced at least one thrombotic event (119). This is lower than the figures reported for families with PC deficiency (132) it should be borne in mind, however, that these families with APC-R were not selected on the severity of thrombophilia as was the case in family studies of PC deficiency. In a population based case control study APC-R was found in 21 percent of patients with a first episode of deep vein thrombosis and in five percent of controls which led to an estimate of the relative risk associated with APC-R of 7 (121). This risk estimate is very similar for that found for PC deficiency.

Because of its high allele frequency homozygous carriers of the factor V Arg506 to Gln alleles are not uncommon. The homozygous abnormality appears much less severe than homozygous PC deficiency since several of the homozygous patients have remained thrombosis free well into adult life (4, 136). Still the risk of thrombosis for those homozygous for the mutation is higher than for those heterozygous (10-fold higher), estimated at 90 fold increased compared to individuals without the mutation (4).

Combined Abnormalities

Deficiencies of PC, PS and antithrombin are rare while APC-R is very common. Because they are so rare these former deficiencies have been studied mostly in referred and highly selected families. In these selected families e.g. with PC deficiency, high risks of thrombosis have been observed (PC deficiency is then said to be clinically dominant), much higher than in relatives of patients homozygous for PC deficiency (PC deficiency is then said to be clinically recessive) (118). This discrepancy in clinical expression cannot be explained by different mutations underlying PC deficiency (37). The most plausible explanation for the difference in clinical expression in PC deficiency arises from the view that more than one abnormality may be required to cause thrombosis, see Fig. 2. In patients with homozygous PC deficiency, two identical defects are present so that their heterozygous relatives will often have just one defect which carries a smaller risk. Individuals with heterozygous PC deficiency from families with striking thrombophilia among heterozygous carriers might be expected to have additional abnormalities contributing to the risk. It has been shown that APC-R may be such a second risk factor and this explains why in family studies among selected families with thrombophilia the risk of thrombosis among non deficient family members was higher

than in the general population (132) many of them had APC R (137) In this study it was shown that the combination of PC deficiency and APC-R conferred a higher risk than each of these abnormalities separately Similar conclusions have been drawn regarding the increased risk of thrombosis following interaction of factor V 506Arg to Gln mutation with the other inhibitor deficiencies PS and antithrombin deficiencies (138-140) The situation with combined factor V 506Arg to Gln and antithrombin mutation is further complicated by their close genetic proximity In some families co-segregation of two genetic defects can occur resulting in high thrombotic risk to all affected individuals (139)

Acquired risk factors are important in the development of thrombosis Unfortunately there are few reported studies that contain quantitative information It has been shown that the risk of thrombosis is further increased among women with PC deficiency who use oral contraceptives (141), and is greatly increased among APC-R women who use oral contraceptives (142) The risk is reported to vary with the type of progestagen used (143)

References

- Egeberg O Inherited antithrombin III deficiency causing thrombophilia *Thromb Diath Haemorrh* 1965 13 516-30
- Dahlback B Carlsson M Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C *Proc Natl Acad Sci USA* 1993 90 1004-8
- Bertina RM Koeleman BP Koster T Rosendaal FR Dirven RJ de Ronde H van der Velden PA Reitsma PH Mutation in blood coagulation factor V associated with resistance to activated protein C *Nature* 1994 369 64-7
- Rosendaal FR Koster T Vandenbroucke JP Reitsma PH High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) *Blood* 1995 85 1504-8
- Voorberg J Roelse J Koopman R Buller H Berends F ten Cate JW Mertens K van Mourik JA Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V *Lancet* 1994 343 1535-6
- Lane DA Mannucci PM, Bauer KA Bertina RM Bochkov NP Boulyjenkov V Chandy M Dahlback B Ginter EK Mileteich JP Rosendaal FR Seligsohn U Inherited thrombophilia Part 2 *Thromb Haemost* 1996 76 (publication Dec 1996)
- Lane DA Caso R Antithrombin structure genomic organisation function and inherited deficiency *Baillieres Clin Haem* 1989 2 961-98
- Blajchman M Austin R Fernandez Rachubinski F Sheffield W Molecular basis of inherited antithrombin deficiency *Blood* 1992 80 2159-71
- Olds RJ Lane DA Mille B Chowdhury V Thein SL Antithrombin the principal inhibitor of thrombin *Semin Thromb Haemostas* 1994 20 353-72
- Bock SC Wion KL Vehar GA Lawn RM Cloning and expression of the cDNA for human antithrombin III *Nucl Acids Res* 1982 10 8113-25
- Chandra T Stackhouse R Kidd VJ Woo SLC Isolation and sequence characterisation of a cDNA clone of human antithrombin III *Proc Natl Acad Sci USA* 1983 80 1845-8
- Prochownik EV Matkam AF Orkin SH Isolation of a cDNA clone for human antithrombin III *J Biol Chem* 1983 258 8389-94
- Bock SC Harris JF Balazs I Tient JM Assignment of the human antithrombin III structural gene to chromosome 1q23.25 *Cytogenet Cell Genet* 1985 39 67-9
- Bock SC Mariman JA Radziejewska E Antithrombin III Utah proline 407 to leucine mutation in a highly conserved region near the inhibitor reactive site *Biochemistry* 1988 27 6171-8
- Olds RJ Lane DA Chowdhury V De Stefano V Leone G Thein SL Complete nucleotide sequence of the antithrombin gene evidence for homologous recombination causing thrombophilia *Biochemistry* 1993 32 4216-24
- Olds RJ Lane DA Chowdhury V Sas G Pabinger I Auberger K Thein SL (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations *Hum Mutat* 1994 4 31-41
- Lane DA Olds RJ Conrad J Boisclair M Bock SC Hultin M Abildgaard U Ireland H Thompson E Sas G Horrelou MH Tamponi G Thein SL Pleiotropic effects of antithrombin strand 1C substitution mutations *J Clin Invest* 1992 90 2422-33
- Lane DA Olds RJ Boisclair M Chowdhury V Thein SL Cooper DN Blajchman M Perry D Emmerich J Atach M Antithrombin III mutation database first update *Thromb Haemost* 1993 70 361-9
- Finazzi G Caccia R Barbui T Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency review of 404 cases *Thromb Haemost* 1987 58 1094
- Lane DA Ireland H Olds RJ Thein SL Perry DJ Atach M Antithrombin III a database of mutations *Thromb Haemost* 1991 66 657-61
- Borg JY Owen MC Soria C Soria J Caen J Carrell RW Proposed heparin binding site in antithrombin based on arginine 47 A new variant Rouen-II 47 Arg to Ser *J Clin Invest* 1988 81 1292-6
- Mille B Watton J Barrowcliffe TW Mani JC Lane DA Role of N and C terminal amino acids in antithrombin binding to pentasaccharide *J Biol Chem* 1994 269 29435-43
- Millar DS Lopez A White D Abraham G Laursen B Holding S Reverter JC Reynand J Martinowitz U Hayes JPLA Kakkar VV Cooper DN Screening for mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis by single strand conformation polymorphism analysis *Human Mutation* 1993 2 324-6
- van Boven HH Olds RJ Thein SL Reitsma PH Lane DA Briet E Vandenbroucke JP Rosendaal FR Hereditary antithrombin deficiency heterogeneity of the molecular basis and mortality in Dutch families *Blood* 1994 84 4209-13
- Jochmans K Lissens W Vervoot R Peeters S De Wale M Liebaers I Antithrombin-Gly 424 Arg a novel point mutation responsible for type I antithrombin deficiency and neonatal thrombosis *Blood* 1994 83 146-51
- Jochmans K Lissens W Yin T Michiels JJ van der Luit L Peerlinck K Vervoot R De Wale M Liebaers I Molecular basis for type I antithrombin deficiency identification of two novel mutations and evidence for a de novo splice mutation *Blood* 1994 84 3742-8
- Millar DS Wacey AI Ribando J Melissari E Laursen B Woods P Kakkar VV Cooper DN Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis *Human Genetics* 1995 94 509-12
- Esmon CT The protein C anticoagulant pathway *Arterioscler Thromb* 1992 12 135-45
- Esmon CT Molecular events that control the protein C anticoagulant pathway *Thromb Haemost* 1993 70 29-35
- Dahlback B The protein C anticoagulant system inherited defects as basis for venous thrombosis *Thromb Res* 1995 77 1-43
- Foster D Davie EW Characterization of a cDNA coding for human protein C *Proc Natl Acad Sci USA* 1984 81 4766-70
- Beckmann RJ Schmidt RJ Santerre RF Plutsky J Citibee GR Long GL The structure and evolution of 1461 amino acid human protein C precursor and its messenger RNA based upon the DNA sequence of cloned human liver cDNAs *Nucleic Acids Res* 1985 13 5233-47
- Foster DC Yoshitake S Davie EW The nucleotide sequence of the gene for human protein C *Proc Natl Acad Sci USA* 1985 82 4673-7
- Plutsky J Hoskins JA Long GL Citibee GR Evolution and organization of the human protein C gene *Proc Natl Acad Sci USA* 1986 83 546-50

35. Patracchini P, Aiello V, Palazzi P, Calzolari E, Bernardi F. Sublocalization of the human protein C gene on chromosome 2q13-q14. *Hum Genet* 1989; 81: 191-2.
36. Reitsma PH, Poort SR, Bernardi F, Gandrille S, Long GL, Sala N, Cooper DN. Protein C deficiency: a database of mutations. For the Protein C & S Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost* 1993; 69: 77-84.
37. Reitsma PH, Bernadi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper D. Protein C deficiency: A database of mutations. 1995 update. *Thromb Haemost* 1995; 73: 876-89.
38. te Lintel Hekkert W, Bertina RM, Reitsma PH. Two RFLPS approximately 7 kb 5' of the human protein C gene. *Nucleic Acids Res* 1988; 16: 11849.
39. Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. *Thromb Haemost* 1995; 74: 81-9.
40. Wacey AI, Pemberton S, Cooper DN, Kakkar VV, Tuddenham EG. A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. *Br J Haematol* 1993; 84: 290-300.
41. Greengard JS, Fisher CL, Villoutreix B, Griffin JH. Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. *Proteins* 1994; 18: 367-80.
42. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. *J Biol Chem* 1993; 268: 2872-7.
43. Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. *Proc Natl Acad Sci USA* 1994; 91: 2728-32.
44. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BM. Inhibition of the intrinsic factor X activating complex by protein S: Evidence for specific binding of protein S to Factor VIII. *Blood* 1995; 86: 1062-71.
45. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG. Reevaluation of the roles of protein S and Gas 6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. *Cell* 1995; 82: 355-8.
46. Benzakour O, Formstone C, Rahman S, Kanthou C, Dennehy U, Scully MF, Kakkar VV, Cooper DN. Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells. *Biochem J* 1995; 308: 481-5.
47. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: protein C, S, C4b-binding protein and thrombomodulin. In: *Haemostasis and Thrombosis*. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Churchill Livingstone, Edinburgh 1994; pp 671-98.
48. Lundwall A, Dackowski W, Cohen E, Shaffer M, Mahr A, Dahlbäck B, Stenflo J, Wydro R. Isolation and sequence of the cDNA for human protein S, a regular of blood coagulation. *Proc Natl Acad Sci USA* 1986; 83: 6716-20.
49. Hoskins JA, Norman DK, Beckmann RJ, Long GL. Cloning and characterization of a human liver cDNA encoding a protein S precursor. *Proc Natl Acad Sci USA* 1987; 84: 349-53.
50. Ploos van Amstel HK, van der Zanden AL, Reitsma PH, Bertina RM. Human protein S cDNA encodes Phe-16 and Tyr 222 in consensus sequences for the post-translational processing. *FEBS Lett* 1987; 222: 186-90.
51. Edenbrandt CM, Lundwall A, Wydro R, Stenflo J. Molecular analysis of the gene for vitamin K dependent protein S and its pseudogene. Cloning and partial gene organization. *Biochemistry* 1990; 29: 7861-8.
52. Ploos van Amstel HK, Reitsma PH, van der Logt CP, Bertina RM. Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. *Biochemistry* 1990; 29: 7853-61.
53. Schmidel DK, Tatro AV, Phelps LG, Tomczak JA, Long GL. Organization of the human protein S genes. *Biochemistry* 1990; 29: 7845-52.
54. Watkins PC, Eddy R, Fukushima Y, Byers MG, Cohen EH, Dackowski WR, Wydro RM, Shows TB. The gene for protein S maps near the centromere of human chromosome 3. *Blood* 1988; 71: 238-41.
55. Ploos van Amstel HK, Reitsma PH, Hamulyak J, de Die Smulders CE, Mannucci PM, Bertina RM. A mutation in the protein S pseudogene is linked to protein S deficiency in a thrombophilic family. *Thromb Haemost* 1989; 62: 897-901.
56. Diepstraten CM, Ploos van Amstel JK, Reitsma PH, Bertina RM. A CCA/CCG neutral dimorphism in the codon for Pro 626 of the human protein S gene PS alpha (PROS1). *Nucleic Acids Res* 1991; 19: 5091.
57. Formstone CJ, Voke J, Tuddenham EGD, Jenkins E, Clark J, Layton M, Nicolaides K, Kakkar VV, Cooper DC. Prenatal exclusion of severe protein S deficiency by indirect RFLP analysis. *Thromb Haemostas* 1993; 69: 931.
58. Marchetti G, Legnani C, Patracchini P, Gemmati D, Ferrati M, Palareti G, Coccheri S, Bernardi F. Study of a protein S gene polymorphism at DNA and mRNA level in a family with symptomatic protein S deficiency. *Br J Haematol* 1993; 85: 173-5.
59. Comp PC. Laboratory evaluation of protein S status. *Semin Thromb Hemost* 1990; 16: 177-81.
60. Zöller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. *Blood* 1995; 85: 3524-31.
61. Duchemin J, Gandrille S, Borgel D, Feurgard P, Alhenc-Gelas M, Matheron C, Dreyfus M, Dupuy E, Juhan-Vague I, Aiach M. The Ser 460 Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. *Blood* 1995; 86: 3436-43.
62. Bertina RM, Ploos van Amstel HK, van Wijngaarden A, Coenen J, Leemhuis MP, Deutz Terlouw PP, van der Linden IK, Reitsma PH. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. *Blood* 1990; 76: 538-48.
63. Borgel D, Duchemin J, Matheron C, Aiach M, Gandrille S. Molecular defects responsible for type I and IIa protein S (PS) deficiencies in a panel of 120 French families. *Thromb Haemostas* 1995; 73: 1256.
64. Reitsma PH, Ploos van Amstel HK, Bertina RM. Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. *J Clin Invest* 1994; 93: 486-92.
65. Gomez E, Poort SR, Bertina RM, Reitsma PH. Identification of eight point mutations in protein S deficiency type I - Analysis of 15 pedigrees. *Thromb Hemost* 1995; 73: 750-5.
66. Ploos van Amstel HK, Huisman MV, Reitsma PH, ten Cate JW, Bertina RM. Partial protein S gene deletion in a family with hereditary thrombophilia. *Blood* 1989; 73: 479-83.
67. Schmidel DK, Nelson RM, Broxson EH, Jr., Comp PC, Marlar RA, Long GL. A 5.3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families. *Blood* 1991; 77: 551-9.
68. Gandrille S, Borgel D, Eschwege Gufflet V, Aillaud M, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sié P, Toulon P, Aiach M. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. *Blood* 1995; 85: 130-8.
69. Hayashi T, Nishioka J, Shigekiyo T, Daito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. *Blood* 1994; 83: 683-90.
70. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. *J Biol Chem* 1994; 269: 31869-80.
71. Nicolaes GAF, Tans G, Thomassen MCLGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of

- functional activity during inactivation of factor Va and factor Va R506Q by activated protein C *J Biol Chem* 1995 270 21158-66
- 72 Shen L, Dahlback B Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa *J Biol Chem* 1994 269 18735-8
- 73 Jenny RJ, Tracy PB, Mann KG The physiology and biochemistry of factor V. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds) Churchill Livingstone, Edinburgh 1994 pp 465-76
- 74 Kane WH, Davie EW Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin *Proc Natl Acad Sci USA* 1986 83 6800-4
- 75 Kane WH, Ichinose A, Hagen FS, Davie EW Cloning of cDNAs coding for the heavy chain region and connecting regions of human factor V, a blood coagulation factor with four types of internal repeats *Biochemistry* 1987 26 6508-14
- 76 Jenny RJ, Pittman DD, Toole JJ, Kilz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG Complete cDNA and derived amino acid sequence of human factor V *Proc Natl Acad Sci USA* 1987 84 4846-50
- 77 Cripe LD, Moore KD, Kane WH Structure of the gene for human coagulation factor V *Biochemistry* 1992 31 3777-85
- 78 Wang H, Riddell DC, Guinto ER, MacGillivray RT, Hamerton JL Localization of the gene encoding human factor V to chromosome 1q21.25 *Genomics* 1988 2 324-8
- 79 Bayston T, Ireland H, Olds RJ, Thein SL, Lane DA A polymorphism in the human coagulation factor V gene *Hum Mol Genet* 1994 3 2085
- 80 Zoller B, Dahlback B Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis *Lancet* 1994 343 1536-8
- 81 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B Activated protein C resistance caused by Arg506Gln mutation in factor Va *Lancet* 1994 343 1361-2
- 82 Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Hackeng TM, Greengard JS Activated protein C resistance: molecular mechanisms *Thromb Haemost* 1995 74 444-8
- 83 Kalafatis M, Bertina RM, Rand MD, Mann KG Characterization of the molecular defect in factor VR506Q *J Biol Chem* 1995 270 4053-7
- 84 Rees DC, Cox M, Clegg JB World distribution of factor V Leiden *Lancet* 1995 346 1133-4
- 85 Ohlin A-K, Marlar RA The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease *Blood* 1995 85 330-6
- 86 Haverkate F, Samama M Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen *Thromb Haemost* 1995 73 151-61
- 87 Ohlin A-K, Marlar RA Mutations in the thrombomodulin gene associated with thromboembolic disease *Thromb Haemost* 1995 73 1096
- 88 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis *Arterioscler Thromb* 1994 14 1080-3
- 89 den Heijer M, Blom HJ, Gerits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ Is hyperhomocysteinemia a risk factor for recurrent thrombosis? *Lancet* 1995 345 882-5
- 90 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Van den Broeke JP, Rosendaal FR Hyperhomocysteinemia as a risk factor for deep vein thrombosis *N Engl J Med* 1996 334 759-62
- 91 Mudd SH, Levy HL, Skovby F Disorders of transsulfuration. In: The metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (eds) McGraw Hill, New York 1989 pp 693
- 92 Malinov MR Homocysteine and arterial occlusive diseases *J Int Med* 1994 236 603
- 93 Frost P, Blom HJ, Milos R, Govette P, Sheppard CA, Mathews RG, Bocus GHJ A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrafolate reductase *Nature Genetics* 1995 10 111-3
- 94 Dolan G, Preston FE Familial plasminogen deficiency and thromboembolism *Fibrinolysis* 1988 2 (S2) 26-34
- 95 Santori MT, Patrassi GM, Theodoridis P, Perin A, Pielrogrande F, Girolami A Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistic analysis in 20 kindreds *Blood Coag Fibrinolysis* 1994 5 889-93
- 96 Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis *Thromb Haemost* 1988 59 18-22
- 97 Tait RC, Walker ID, Islam SIA, Mitchell R, Davidson JF Plasminogen levels and putative prevalence of deficiency in 4500 blood donors *Br J Haematol* 1991 77 (S1) 10
- 98 Ichinose A, Espling ES, Takamatsu J, Saito H, Shimvozo K, Maruyama I, Petersen TE, Davie EW Two types of abnormal plasminogen genes in families with a predisposition for thrombosis *Proc Natl Acad Sci USA* 1991 88 115-9
- 99 Lijnen HR, Hoylaerts M, Collen D Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine rich glycoprotein *J Biol Chem* 1980 255 10214-22
- 100 Engesser L, Kluff C, Briet E, Brommer EJ Familial elevation of plasma histidine rich glycoprotein in a family with thrombophilia *Br J Haematol* 1987 67 355-8
- 101 Castaman G, Ruggeri M, Buret F, Rodeghiero F High levels of histidine rich glycoprotein and thrombotic diathesis. Report of two unrelated families *Thromb Res* 1993 69 279-305
- 102 Souto JC, Gari M, Mateo J, Falcon L, Borrell M, Fontcuberta J Congenital histidine rich glycoprotein deficiency and familial thrombophilia: a new case *Thromb Haemost* 1995 73 952
- 103 Shigekiyo T, Kanazuka M, Azuma H, Oshima T, Kasaka K, Saito H Congenital deficiency of histidine rich glycoprotein: failure to identify abnormalities in routine laboratory assays of hemostatic function, immunologic function and trace elements *J Lab Clin Med* 1995 125 719-23
- 104 Beitina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJP Hereditary heparin cofactor II deficiency and the risk of development of thrombosis *Thromb Haemostas* 1987 57 196-200
- 105 Bancsi LF, van der Linden IK, Bertina RM Beta 2-glycoprotein I deficiency and the risk of thrombosis *Thromb Haemost* 1992 67 649-53
- 106 Simon P, Lazarro AR, Corer E, Salmustaro G, Girolami A Constitutional heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds *Blood Coag Fibrinolysis* 1990 1 351-6
- 107 Sie P, Dupouy D, Pichon J, Boneu B Constitutional heparin cofactor II deficiency associated with recurrent thrombosis *Lancet* 1985 2 414-6
- 108 Blinder MA, Andeisson TR, Abildgaard U, Tolletsen DM Heparin cofactor II Oslo: mutation of Arg 180 to His decreases the affinity for dermatan sulphate *J Biol Chem* 1989 264 1128-33
- 109 Halbmayr WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from venous and/or arterial thromboembolism *Thromb Haemost* 1992 68 285-90
- 110 Koster T, Rosendaal FR, Briet E, Vandenbroucke JP, John Hagemann S factor and deep vein thrombosis. Leiden Thrombophilia Study *Br J Haematol* 1994 87 422-4
- 111 Koster T, Blom AD, Briet E, Vandenbroucke JP, Rosendaal FR Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis *Lancet* 1995 345 152-5
- 112 Griffin JH, Evatt B, Wideman C, Fernandez JA Anticoagulant protein C pathway defective in majority of thrombotic patients *Blood* 1993 82 1989-93

- 113 Heijboer H, Brandjes DP, Buller HR, Stuijk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. *N Engl J Med* 1990; 323: 1512-6
- 114 Tait RC, Walker ID, Petty DJ, Carrell RW, Islam SIA, McCall F, Mitchell R, Davidson JF. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. *Thromb Haemost* 1991; 65: 839
- 115 Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF. Protein C activity in healthy volunteers-influence of age, sex, smoking and oral contraceptives. *Thromb Haemost* 1993; 70: 218-5
- 116 Tait RC, Walker ID, Islam SIA, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. *Brit J Haematol* 1993; 84: 476-80
- 117 Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. *Thromb Haemost* 1995; 73: 87-93
- 118 Miletech J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. *N Engl J Med* 1987; 317: 991-6
- 119 Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. *N Engl J Med* 1994; 330: 517-22
- 120 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletech JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. *N Engl J Med* 1995; 332: 912-7
- 121 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. *Lancet* 1993; 342: 1503-6
- 122 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. *Clin Haematol* 1981; 10: 369-90
- 123 Hersh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. *Am J Med* 1989; 87 (suppl 3B): 34S-38S
- 124 Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S. Study of 78 women. *Thromb Haemost* 1990; 63: 319-20
- 125 Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). *Blood* 1995; 85: 2756-61
- 126 Rosendaal FR, Heijboer H. Mortality related to thrombosis in congenital antithrombin III deficiency. *Lancet* 1991; 337: 1545
- 127 De Stefano V, Leone G. Mortality related to thrombosis in congenital antithrombin III deficiency. *Lancet* 1991; 337: 847-8
- 128 Cosgriff TM, Bishop DP, Hershgold EJ, Skolnick MH, Martin BA, Baty BJ, Carlson KJ. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. *Medicine* 1983; 62: 209-20
- 129 Rosendaal FR, Heijboer H, Briet E, Buller H, Brandjes DPM, DeBruin K, Hommes DW, Vandenbroucke JP. Mortality in hereditary antithrombin III deficiency - 1830-1989. *Lancet* 1991; 337: 260-2
- 130 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. *J Clin Invest* 1981; 68: 1370-3
- 131 Bovill EG, Bauer KA, Dicketman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. *Blood* 1989; 73: 712-7
- 132 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. *Lancet* 1993; 341: 134-8
- 133 Schwaz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. *Blood* 1984; 64: 1297-300
- 134 Broekmans AW, Bertina RM, Remalda Poot J, Engesser L, Muller HP, Leeuw JA, Michiels JJ, Brommer EJ, Briet E. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. *Thromb Haemost* 1985; 53: 273-7
- 135 Faiori EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. *Thromb Haemost* 1993; 70: 1067-71
- 136 Greengard JS, Eichinger S, Griffin JH, Bauer KA. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg → Gln mutation in the gene for factor V. *N Engl J Med* 1994; 331: 1559-62
- 137 Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. *Blood* 1994; 84: 1031-5
- 138 Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. *Blood* 1995; 85: 3518-23
- 139 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. *Thromb Haemost* 1996; 75: 417-21
- 140 Ireland H, Bayston TA, Chowdhury V, Thein SL, Conard J, Pabinger I, Lane DA. Factor V Leiden as an independent risk factor for thrombosis and antithrombin deficiency type II heparin binding site. *Thromb Haemost* 1995; 73: 1361 (Abstr 1764)
- 141 Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. *Thromb Haemost* 1994; 71: 548-52
- 142 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet* 1994; 344: 1453-7
- 143 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutations of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. *Lancet* 1995; 346: 1593-6
- 144 Gomez E, Ledford MR, Pegelow CH, Reitsma PH, Bertina RM. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. *Thromb Haemost* 1994; 71: 723-6
- 145 Borgel D, Gandrille S, Gouault Heilmann M, Aiach M. First frameshift mutation in the active protein S gene associated with a quantitative hereditary deficiency. *Blood Coagul Fibrinolysis* 1994; 5: 593-600
- 146 Formstone CJ, Wacey AI, Berg L, Rahman S, Bevan D, Rowley M, Voke J, Francesco B, Legnani F, Simioni P, Girolami A, Tuddenham EGD, Kakkar VV, Cooper DC. Detection and characterisation of seven novel protein S (PROS) gene lesions. Evaluation of reverse transcript-Polymerase Chain Reaction as a mutation screening strategy. *Blood* 1995; 86: 2632-41
- 147 Briet E, Engesser L, Brommer EJP, Broekmans AW, Bertina RM. Thrombophilia: its causes and a rough estimate of its prevalence. *Thromb Haemost* 1987; 58: 39
- 148 Scharer I, Hach-Wunderle V, Heyland H, Kuhn C. Incidence of defective tPA release in 158 unrelated young patients with venous thrombosis in comparison to PC-, PS-, ATIII-, fibrinogen- and plasminogen deficiency. *Thromb Haemost* 1987; 58: 72
- 149 Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. *Thromb Haemost* 1989; 61: 50-4
- 150 Tabernero MD, Tomas JF, Alberca I, Ortao A, Lopez Borrascas A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. *Am J Hematol* 1991; 36: 249-54

Received April 16 1996 Accepted after revision July 30 1996